Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 19.63.
Forward PE Ratio (19.63) = Close Price ($513.12) / Consensus Forward EPS ($26.15)
FORWARD PE RATIO
19.63
SECTOR MEDIAN · HEALTHCARE
19.91
median of 68 covered companies
CURRENT VS SECTOR MEDIAN
-1.43%
vs the sector median at left
United Therapeutics Corporation
Market Cap
$21.78B
Forward PE Ratio
19.63
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| United Therapeutics Corporation (UTHR) | $21.78B | 19.63 |
| STERIS plc (STE)vs › | $23.19B | 23.33 |
| Zimmer Biomet Holdings, Inc. (ZBH)vs › | $19.54B | 11.84 |
| Viatris Inc. (VTRS)vs › | $19.01B | 6.53 |
| West Pharmaceutical Services, Inc. (WST)vs › | $24.85B | 39.38 |
| Incyte Corporation (INCY)vs › | $25.91B | 33.97 |
| Medpace Holdings, Inc. (MEDP)vs › | $17.33B | 35.27 |
| Quest Diagnostics Incorporated (DGX)vs › | $26.97B | 21.84 |
| Labcorp Holdings Inc. (LH)vs › | $27.58B | 18.35 |
| Solventum Corporation (SOLV)vs › | $15.51B | 12.51 |
Trailing P/E
18.4
reported TTM EPS
Forward P/E
19.6
consensus next-FY EPS
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $26.15 implies -6.3% EPS decline vs the reported trailing $27.91.
At today's $513.12 close, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $26.15 | $23.74 – $27.31 | 11 | 19.6x |
| 2027-12-31 | $28.90 | $23.10 – $35.16 | 11 | 17.8x |
| 2028-12-31 | $34.67 | $23.30 – $46.90 | 10 | 14.8x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute